Nicholas W Warne
age ~62
from Andover, MA
- Also known as:
-
- Nicholas W Warm
- Nicholas W Worne
- Nicholai W Warne
- Nicolas W Warne
- Nick Warne
- Nichola Warne
- Phone and address:
-
27 Farrwood Dr, Andover, MA 01810
978-749-6649
Nicholas Warne Phones & Addresses
- 27 Farrwood Dr, Andover, MA 01810 • 978-749-6649
- Fruitport, MI
- 28 Park Forest Dr, Pittsford, NY 14534 • 585-387-0304
- Methuen, MA
- Waynesboro, PA
- Collins, NY
- Ridgefield, CT
- Lafayette, IN
- Ada, MI
Work
-
Company:PfizerAug 2018
-
Position:Vice president pharmaceutical r and d
Education
-
Degree:Doctorates, Doctor of Philosophy
-
School / High School:Purdue University1984 to 1990
-
Specialities:Philosophy, Chemistry
Industries
Biotechnology
License Records
Nicholas L Warne
License #:
981042 - Expired
Category:
Swimming Pool Operator
Issued Date:
Jun 5, 2012
Effective Date:
Jun 10, 2016
Expiration Date:
Jun 5, 2016
Type:
Swimming Pool Operator
Name / Title
Company / Classification
Phones & Addresses
Director Of Formulations
Wyeth Sodexho Building F
Eating Places
Eating Places
1 Burtt Rd, Andover, MA 01810
Director Of Formulations
Wyeth Sodexho Building F
Eating Place
Eating Place
1 Burtt Rd, Andover, MA 01810
978-247-2516
978-247-2516
Us Patents
-
Method Of Treating Inflammatory Bowel Disease Using A Topical Formulation Of Il-11
view source -
US Patent:6540993, Apr 1, 2003
-
Filed:Sep 15, 2000
-
Appl. No.:09/662994
-
Inventors:Nicholas W. Warne - Andover MA
Camille L. Bedrosian - Belmont Hills MA
Paul F. Schendel - Wayland MA -
Assignee:Wyeth - Madison NJ
-
International Classification:A61K 3819
-
US Classification:424 852, 514 2, 514 8, 514 12, 514885, 514867
-
Abstract:Provided by the present invention are topical formulations of Interleukin-11 and methods for treating a variety of disorders, including inflammatory bowel diseases (e. g. , Crohns disease, ulcerative colitis, indeterminate colitis, and infectious colitis), mucositis (e. g. , oral mucositis, gastrointestinal mucositis, nasal mucositis, and proctitis), necrotizing enterocolitis, inflammatory skin disorders (e. g. , psoriasis, atopic dermatitis, and contact hypersensitivity), aphthous ulcers, pharyngitis, esophagitis, peptic ulcers, gingivitis, periodontitis, and ocular diseases (e. g. , conjunctivitis, retinitis, and uveitis).
-
Human Antibodies That Bind Human Il-12 And Methods For Producing
view source -
US Patent:6914128, Jul 5, 2005
-
Filed:Mar 24, 2000
-
Appl. No.:09/534717
-
Inventors:Jochen Salfeld - North Grafton MA, US
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Shrewsbury MA, US
Daniel Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Melrose MA, US
Nicholas W. Warne - Andover MA, US
Angela Myles - Andover MA, US
John Gawain Elvin - Cambridge, GB
Alexander Robert Duncan - Little Shelford, GB
Elaine Joy Derbyshire - Royston, GB
Sara Carmen - Cambridge, GB
Thor Las Holtet - Royston, GB
Sarah Leila Du Fou - Hitchen, GB
Stephen Smith - Ely, GB -
Assignee:Abbott GmbH & Co. KG - Wiesbaden
-
International Classification:C07K016/18
C07K016/24
C12P021/08 -
US Classification:5303873, 5303871, 5303879, 53038815, 53038824, 5303892, 530351
-
Abstract:Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
Hydroxyethyl Starch—Containing Polypeptide Compositions
view source -
US Patent:6982080, Jan 3, 2006
-
Filed:Mar 17, 2003
-
Appl. No.:10/390053
-
Inventors:Nicholas W. Warne - Andover MA, US
Rebecca L. Koval - Billerica MA, US
John Carpenter - Littleton CO, US
Theodore W. Randolph - Longmont CO, US
Suchart Chongpraset - Bangkok, TH -
Assignee:Wyeth - Madison NJ
The Regents of the University of Colorado - Boulder CO -
International Classification:A61K 38/02
A61K 38/20
A61K 47/26
A61K 47/36 -
US Classification:424 852, 514 2, 514 21, 514777, 514778
-
Abstract:The invention provides compositions containing hydroxyethyl starch and polypeptides, including therapeutic polypeptides such as interleukin-11, that provide for enhanced stability of the polypeptide following storage at room temperature or elevated temperatures.
-
Formulations For Il-11
view source -
US Patent:7033992, Apr 25, 2006
-
Filed:Oct 5, 2001
-
Appl. No.:09/971813
-
Inventors:Nicholas W. Warne - Andover MA, US
Rebecca L. Ingram - Nutting Lake MA, US
Shannon Macmillan - Hollis NH, US -
Assignee:Genetics Institute LLC - Cambridge MA
-
International Classification:A01N 37/18
C07K 14/00 -
US Classification:514 2, 530351
-
Abstract:Provided by the present invention are novel compositions and methods for obtaining concentrated preparations of IL-11 and formulations of IL-11 suitable for storage and administration.
-
Protein Formulations With Reduced Viscosity And Uses Thereof
view source -
US Patent:7390786, Jun 24, 2008
-
Filed:Dec 21, 2006
-
Appl. No.:11/644079
-
Inventors:Nicholas W. Warne - Andover MA, US
Pilarin Elizabeth Louise Nichols - Andover MA, US
Paulo Jorge Loureiro - Lawrence MA, US -
Assignee:Wyeth - Madison NJ
-
International Classification:A61K 38/00
-
US Classification:514 12
-
Abstract:Protein formulations and methods for reducing the viscosity of a protein formulation are provided. The method for reducing the viscosity of a protein formulation comprises adding a viscosity reducing agent, such as calcium chloride or magnesium chloride to the protein formulation.
-
Hydroxyethyl Starch-Containing Polypeptide Compositions
view source -
US Patent:7449444, Nov 11, 2008
-
Filed:Sep 27, 2005
-
Appl. No.:11/236213
-
Inventors:Nicholas W. Warne - Andover MA, US
Rebecca L. Koval - Billerica MA, US
John Carpenter - Littleton CO, US
Theodore W. Randolph - Longmont CO, US
Suchart Chongpraset - Bangkok, TH -
Assignee:Wyeth - Madison NJ
The Regent of the University of Colorado - Boulder CO -
International Classification:A61K 38/02
A61K 47/26
A61K 47/36 -
US Classification:514 2, 514777, 514778
-
Abstract:The invention provides compositions containing hydroxyethyl starch and polypeptides, including therapeutic polypeptides such as interleukin-11, that provide for enhanced stability of the polypeptide following storage at room temperature or elevated temperatures.
-
Human Antibodies That Bind Human Il-12
view source -
US Patent:7504485, Mar 17, 2009
-
Filed:Jul 1, 2004
-
Appl. No.:10/884830
-
Inventors:Jochen G. Salfeld - North Grafton MA, US
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Shrewsbury MA, US
Daniel Edward Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary NC, US
Nicholas W. Warne - Andover MA, US
Angela Myles - Andover MA, US
John Gawain Elvin - Cambridge, GB
Alexander Robert Duncan - Cambridge, GB
Elaine J. Derbyshire - Royston, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Royston, GB
Sarah Leila Du Fou - Hitchen, GB -
Assignee:Abbott GmbH & Co., KG - Wiesbaden
-
International Classification:C07K 16/24
A61K 39/395 -
US Classification:53038823, 4241451
-
Abstract:Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
Anti Aβ Antibody Formulation
view source -
US Patent:7635473, Dec 22, 2009
-
Filed:Jan 27, 2006
-
Appl. No.:11/342353
-
Inventors:Nicholas W. Warne - Andover MA, US
Donna Luisi - North Andover MA, US
Angela Kantor - Pepperell MA, US -
Assignee:Janssen Alzheimer Immunotherapy - Little Island, County Cork
Wyeth - Madison NJ -
International Classification:A61K 39/395
A61K 39/00 -
US Classification:4241331, 4241521
-
Abstract:The present invention provides formulations for maintaining the stability of Aβ binding polypeptides, for example, Aβ antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide aggregates, low molecular weight polypeptide degradation fragments, and mixtures thereof. The formulations of the invention optionally comprise a tonicity agent, such as mannitol, and a buffering agent or amino acid such as histidine. The formulations are suitable for several different routes of administration.
Resumes
Vice President Pharmaceutical R And D
view sourceLocation:
400 Crossing Blvd, Bridgewater, NJ 08807
Industry:
Biotechnology
Work:
Pfizer
Vice President Pharmaceutical R and D
Pfizer
Senior Director, Formulations
Pfizer 1990 - 2009
Director Formulation and Process Development
Genetics Institute 1990 - 2000
Staff Scientist
Vice President Pharmaceutical R and D
Pfizer
Senior Director, Formulations
Pfizer 1990 - 2009
Director Formulation and Process Development
Genetics Institute 1990 - 2000
Staff Scientist
Education:
Purdue University 1984 - 1990
Doctorates, Doctor of Philosophy, Philosophy, Chemistry University of Rochester 1980 - 1984
Bachelors, Bachelor of Science, Biochemistry
Doctorates, Doctor of Philosophy, Philosophy, Chemistry University of Rochester 1980 - 1984
Bachelors, Bachelor of Science, Biochemistry
Nick Warne
view source
David Nicholas Warne
view source
Nicholas Warne
view sourceFriends:
Maggie Brown, Nick Atkins, Jo Jimima Hooker, Tim Holme, Graham Pascoe, Ben Jones
Nicholas Warne
view source
Nicholas James Warne
view sourceYoutube
News
Live updates of FDA meeting on Pfizer's Covid vaccines for kids ages 5 to 11
view source- about accidentally giving too strong a dose to children under 11, Pfizer will issue new instructions and dilution warnings with its vaccines for younger age groups, Dr. Nicholas Warne, the company's vice president for pharmaceutical research and development, told the FDA's vaccine advisory committee.
- Date: Oct 26, 2021
- Category: More news
- Source: Google
Googleplus
Nicholas Warne
Get Report for Nicholas W Warne from Andover, MA, age ~62